Alliancebernstein L.P. Fate Therapeutics Inc Transaction History

Alliancebernstein L.P.

$287 Billion
Q3 2024

A detailed history of Alliancebernstein L.P. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Alliancebernstein L.P. holds 146,580 shares of FATE stock, worth $194,951. This represents 0.0% of its overall portfolio holdings.

Number of Shares

146,580

Previous 146,580 -0.0%

Holding current value

$194,951

Previous $480,000 6.88%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.26 - $7.08 $150,612 - $327,096	46,200 Added 46.03%	146,580 $480,000
Q1 2024 May 14, 2024	SELL	$3.54 - $8.35 $213,745 - $504,173	-60,380 Reduced 37.56%	100,380 $736,000
Q4 2023 Feb 14, 2024	SELL	$1.65 - $3.94 $1,320 - $3,152	-800 Reduced 0.5%	160,760 $601,000
Q3 2023 Nov 14, 2023	BUY	$2.02 - $5.04 $69,548 - $173,527	34,430 Added 27.08%	161,560 $342,000
Q2 2023 Aug 15, 2023	BUY	$4.76 - $6.59 $120,570 - $166,924	25,330 Added 24.88%	127,130 $605,000
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $848,000 - $2.22 Million	-200,000 Reduced 66.27%	101,800 $580,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $1.97 Million - $4.77 Million	200,000 Added 196.46%	301,800 $3.05 Million
Q3 2022 Nov 15, 2022	SELL	$21.04 - $36.06 $841,389 - $1.44 Million	-39,990 Reduced 28.2%	101,800 $2.28 Million
Q2 2022 Aug 15, 2022	SELL	$17.78 - $42.39 $2,791 - $6,655	-157 Reduced 0.11%	141,790 $3.51 Million
Q1 2022 May 13, 2022	BUY	$29.67 - $60.28 $10,592 - $21,519	357 Added 0.25%	141,947 $5.5 Million
Q3 2021 Nov 10, 2021	SELL	$59.27 - $95.73 $35,562 - $57,438	-600 Reduced 0.42%	141,590 $8.39 Million
Q2 2021 Jul 30, 2021	BUY	$67.25 - $92.52 $875,595 - $1.2 Million	13,020 Added 10.08%	142,190 $12.3 Million
Q1 2021 May 06, 2021	BUY	$72.16 - $117.4 $2.16 Million - $3.52 Million	29,970 Added 30.21%	129,170 $10.7 Million
Q4 2020 Feb 08, 2021	BUY	$38.09 - $100.95 $297,102 - $787,410	7,800 Added 8.53%	99,200 $9.02 Million
Q3 2020 Nov 12, 2020	BUY	$30.41 - $40.5 $170,296 - $226,800	5,600 Added 6.53%	91,400 $3.65 Million
Q2 2020 Aug 13, 2020	BUY	$20.21 - $35.23 $103,071 - $179,672	5,100 Added 6.32%	85,800 $2.94 Million
Q1 2020 May 14, 2020	BUY	$17.28 - $31.88 $162,432 - $299,672	9,400 Added 13.18%	80,700 $1.79 Million
Q4 2019 Feb 18, 2020	BUY	$13.39 - $20.73 $37,492 - $58,044	2,800 Added 4.09%	71,300 $1.4 Million
Q2 2019 Aug 14, 2019	BUY	$15.61 - $20.44 $135,807 - $177,828	8,700 Added 14.55%	68,500 $1.39 Million
Q1 2019 May 14, 2019	BUY	$13.15 - $18.71 $27,615 - $39,291	2,100 Added 3.64%	59,800 $1.05 Million
Q4 2018 Feb 13, 2019	BUY	$11.48 - $16.98 $173,348 - $256,398	15,100 Added 35.45%	57,700 $740,000
Q3 2018 Nov 08, 2018	BUY	$8.75 - $16.29 $131,250 - $244,350	15,000 Added 54.35%	42,600 $694,000
Q2 2018 Aug 13, 2018	BUY	$9.16 - $13.48 $152,056 - $223,768	16,600 Added 150.91%	27,600 $313,000
Q1 2018 May 14, 2018	BUY	$6.3 - $13.77 $69,300 - $151,470	11,000 New	11,000 $107,000

Others Institutions Holding FATE

# of Institutions

178

Shares Held

113M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $129M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Fate Therapeutics Inc Transaction History